Naringenin pretreatment attenuates hepatic ischemia-reperfusion injury by activating the PI3K-Akt signaling pathway

Figure 4 Screen of the mechanisms that naringenin reduces the occurrence of hepatic ischemia-reperfusion injury utilizing network pharmacology analysis. A: Common genes display of potential target genes of naringenin and liver ischemia-reperfusion injury genes; B: Protein-protein interaction network diagram of naringenin and ischemia-reperfusion injury common genes constructed from String database; C: Gene Ontology analysis of common genes; D: Kyoto Encyclopedia of Genes and Genomes analysis of common genes; E: Western blots showing protein expression levels of p-phosphatidylinositol 3-kinase (PI3K) and p-protein kinase B (Akt); F and G: Densitometric quantification of p-PI3K and p-Akt protein levels normalized to PI3K and Akt (n = 3). ^aP < 0.05 vs the Sham group, ^bP < 0.05 vs the ischemia-reperfusion injury group. NAR: Naringenin; IRI: Ischemia-reperfusion injury; PI3K: Phosphatidylinositol 3-kinase; Akt: Protein kinase B.